Eagle Pharmaceuticals Says Rights Plan Extension Is Not Response to Specific Takeover Threat

• Eagle Pharmaceuticals extended its stockholder rights plan by one year to October 30, 2027, effective immediately.
• The extension responds to significant dislocation in the common stock’s trading price, not a specific takeover threat.
• The plan triggers at 10% beneficial ownership, or 15% for passive institutional investors.
• Once triggered, each eligible right allows holders other than the acquiring person to buy shares worth twice the $20 exercise price.
• The board remains able to consider acquisition proposals it believes serve the company’s and all stockholders’ best interests.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eagle Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610301305PRIMZONEFULLFEED9857158) on October 30, 2026, and is solely responsible for the information contained therein.